Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 36 papers were listed this time. Here's a couple in our areas of research interest:
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med. 2012 Sep 13. [Epub ahead of print] PubMed PMID: 22975761.
Blohmer JU, Rezai M, Kümmel S, et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ. 2012 Sep 11. [Epub ahead of print] PubMed PMID: 22966753.
